FDA approves Forest’s Combunox for pain

Share this article:
The FDA has approved Forest Laboratories' drug Combunox for use in the treatment of moderate to severe pain.
Combunox is a combination of the drug oxycodone, considered to be 10 times more potent than codeine, with the pain reducer ibuprofen.
Forest Laboratories said Combunox provides physicians with a new option for the management of pain typically experienced by patients after surgery or an injury. The New York-based drug maker said it expects to begin selling Combunox in early 2005. 
Combunox was licensed to Forest by London investment firm BTG PLC. Under the terms of the licensing agreement, Forest is responsible for manufacturing, sales and marketing activities of the product in the United States. Forest also has marketing rights in Canada and the United Kingdom, and sub-licensing rights in all other countries of the world.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.